<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381651</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangEC5040</org_study_id>
    <nct_id>NCT03381651</nct_id>
  </id_info>
  <brief_title>Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma</brief_title>
  <official_title>Different Radiation Dose of Neoadjuvant Chemoradiation Followed By Surgery in Treating Patients With Locally Advanced, Resectable Thoracic Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal cancer is one of the most common cancers worldwide, while more than half new cases
      and deaths occurred in China. Surgery is the main curative treatment for this disease, the
      5-year survival of EC remains poor, since most diseases are diagnosed at advanced stages.

      In last decades, several large clinical trials and meta-analyses have demonstrated that
      neo-adjuvant chemoradiotherapy followed by surgery can significantly increase the overall
      survival of patients with EC compared with surgery alone, while no effect of nCRT was
      apparent on postoperative health-related quality of life . However, the optimal radiation
      dose and surgery timing are still unknown.

      The investigators hypothesize that patients who receive higher dose (50.4Gy/28F) of
      neoadjuvant chemoradiation will have better pathologic response and progress-free survival
      compared to lower dose (41.4Gy/23F) of chemoradiation followed by surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 22, 2018</start_date>
  <completion_date type="Anticipated">February 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 year</time_frame>
    <description>Time from randomization to tumor progression or any deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate in each arm</measure>
    <time_frame>analysis is completed 4 weeks after surgery</time_frame>
    <description>no cancer cells seen microscopically at the resection margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete pathological response rate</measure>
    <time_frame>analysis is completed 4 weeks after surgery</time_frame>
    <description>using the Chirieac grading system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications in each study arm</measure>
    <time_frame>30 and 90 days after surgery</time_frame>
    <description>According to the NCI CTC3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure pattern</measure>
    <time_frame>3 year</time_frame>
    <description>including local recurrence or distant metastasis or both</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>by intention to treat and per protocol analyses in each study arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Esophageal Carcinoma</condition>
  <condition>Neoadjuvant Chemoradiation</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemoradiation: RT: 50.4Gy/28F/5.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 6 wks; Surgery: 4-6 weeks after nCRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemoradiation: RT: 41.4Gy/23F/4.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 5 wks; Surgery: 4-6 weeks after nCRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation</intervention_name>
    <description>50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly</description>
    <arm_group_label>Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation</intervention_name>
    <description>41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly</description>
    <arm_group_label>Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age:18-70 years

        Histologically verified squamous carcinoma of the thoracic esophagus.

        Patients with performance status 0-1 according to the Eastern Cooperative Oncology Group
        (ECOG) scale at the pre CRT evaluation and judges to be fit for surgery at the pre and post
        CRT evaluations.

        Tumors should be resectable or potentially resectable and without distant metastasis, as
        assessed before neoadjuvant CRT, including clinical stage T2-4N0M0 or T1-4N1M0 according to
        the 6th AJCC system.

        Joined the study voluntarily and signed informed consent form

        No surgical contraindications

        No serious system dysfunction and immuno-deficiency, Adequate organ function including the
        following: Hemoglobin ≥10 g/dL, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L,
        TBIL&lt;1.5 x ULN, ALT and AST ≤ 2.5 x ULN, creatinine≤1.5 x ULN

        Exclusion Criteria:

        Cervical esophageal cancer (The upper end of the lesion is in the esophagus of the cervical
        segment).

        Patients with biopsy (by endoscopic ultrasound, laparoscopy, or laparotomy) proven
        metastatic supraclavicular or celiac nodes are ineligible.

        Invasion of the tracheobronchial tree or aorta

        Tracheoesophageal fistula

        Concurrent pregnancy or lactation

        Severe diabetes mellitus with poor blood glucose control

        History of a second malignancy

        Patients being unable to undergo esophageal reconstruction with gastric tube, due to prior
        surgery.

        Patients undergoing esophageal reconstruction with jejunum.

        Patients have allergy reaction or contraindications to taxanes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weimin Mao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Caner Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoqin Qiu, M.D.</last_name>
    <phone>+86-571-88128182</phone>
    <email>qiugq@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoqin Qiu, M.D.</last_name>
      <phone>+86-571-88128182</phone>
      <email>qiugq@zjcc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.</citation>
    <PMID>21684205</PMID>
  </reference>
  <reference>
    <citation>Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.</citation>
    <PMID>26254683</PMID>
  </reference>
  <reference>
    <citation>Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086-92. doi: 10.1200/JCO.2007.12.9593.</citation>
    <PMID>18309943</PMID>
  </reference>
  <reference>
    <citation>Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007 Mar;8(3):226-34.</citation>
    <PMID>17329193</PMID>
  </reference>
  <reference>
    <citation>Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Sprangers MAG, van Lanschot JJB. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. J Clin Oncol. 2018 Jan 20;36(3):268-275. doi: 10.1200/JCO.2017.73.7718. Epub 2017 Nov 21.</citation>
    <PMID>29161204</PMID>
  </reference>
  <reference>
    <citation>van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.</citation>
    <PMID>22646630</PMID>
  </reference>
  <reference>
    <citation>Teoh AY, Chiu PW, Yeung WK, Liu SY, Wong SK, Ng EK. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2013 Jan;24(1):165-71. doi: 10.1093/annonc/mds206. Epub 2012 Aug 10.</citation>
    <PMID>22887465</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>January 27, 2018</last_update_submitted>
  <last_update_submitted_qc>January 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Qixun Chen</investigator_full_name>
    <investigator_title>Director, Head of thoracic surgery</investigator_title>
  </responsible_party>
  <keyword>Radiation dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

